Newly activated UI Cancer Center clinical trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about a study, please email [email protected] or call 312-355-5112.

RiMO: Phase 1 Dose-Escalation Study of RiMO-2 with Radiation in Advanced Tumors
Principal Investigator: Lawrence Feldman, MD
Research Sponsor: RiMO Therapeutics, Inc.

NRG-G1004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch repair (dMMR) Metastatic Colorectal Cancer
Principal Investigator: Neeta Venepalli, MD
Research Sponsor: NRG Oncology

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105, E4512 and EA5142
Principal Investigator: Ardaman Shergill, MC
Research Sponsor: Alliance

NRG-GU006: A Phase II, Double-blinded, Placebo-controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Principal Investigator: David Peace, MD
Research Sponsor: NRG Oncology

Translate »